FEROX STRATEGIES

Lobbying for FRESENIUS KABI USA LLC · Generic and biosimilar pharmaceutical manufacturer

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Illinois · House · Senate · $50,000.00 income · posted Oct 20, 2025

Lobbying activity 3

Health Issues

General healthcare issues related to generic and biosimilar industries.

Pharmacy

General patent issues related to generic and biosimilar industries.

Trade (domestic/foreign)

General issues related to trade.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.